Fennec Pharmaceuticals Inc.

NASDAQ:FENC

Biotechnology

Healthcare
$13.33 -1.34%

-$0.12 today

Market cap
$470.62M
Beta
1.08
P/E (TTM)
-36.3
EPS (TTM)
-$0.24
52W Low $5.65High $10.45

Volume 0.59M

Average 0.26M

FENC Cost of Revenue

Direct costs of producing the goods and services sold, such as materials, manufacturing, and service delivery.

Fennec Pharmaceuticals Inc.NASDAQ: FENC

Cost of Revenue · Q1 FY2026 · quarter ended Mar 2026

Cost of revenue growth accelerates

Q1 FY2026 cost of revenue of $570K rose 52.8% year over year, ahead of the +31.7% change in trailing-twelve-month cost of revenue. Sequentially, it fell 67.7% from the prior quarter. Over 3 fiscal years it compounded at +252.4% a year.

Context

  • Cost of revenue amounted to 8.4% of revenue in FY2025, up 1.7 pp from a year earlier.
  • Cost of revenue increased in 3 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth of +52.8% holds above the trailing-twelve-month pace of +31.7%.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterMar 2026
$570K-67.7% QoQ
Last fiscal yearDec 2025
$3.76M+18.2% YoY
LTMMar 2026
$3.96M+31.7% YoY
Cost of Revenue past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+52.8%——
1 year+18.2%——
3-year CAGR+252.4%——
5-year CAGR——
10-year CAGR——

Cost of Revenue history

USD · from the income statement

Latest · FY2025
3.76M USD
Year-over-year change
+18.2%

Cost of Revenue vs competitors

How FENC compares with its peers on the latest reported figures

  • FENC's LTM Mar 2026 cost of revenue of $3.96M is the 4th highest of the 11 companies compared; the peer median is $800K.
  • Its year-over-year change of +31.7% is the 2nd highest of 7, against a peer median of +12.4%.
  • Cost of revenue amounts to 7.8% of revenue for FENC, versus a peer median of 9.9%.
FENC Competitors Peer median
Cost of Revenue for FENC and competitors
Company Period LTM YoY 3-year CAGR% of revenue
RNACCartesian Therapeutics, Inc.LTM Mar 2026$12.8M ——721.0%
AVTXAvalo Therapeutics, Inc.LTM Mar 2026$10.68M +89.7%—18096.6%
NAUTNautilus Biotechnology, Inc.LTM Mar 2026$6.32M -43.5%+23.7%—
FENCFennec Pharmaceuticals Inc.LTM Mar 2026$3.96M +31.7%+252.4%7.8%
CRBUCaribou Biosciences, Inc.LTM Mar 2026$1.95M -96.9%+0.0%17.4%
ENTAEnanta Pharmaceuticals, Inc.LTM Mar 2026$1.21M ——1.7%
PRLDPrelude Therapeutics IncorporatedLTM Mar 2026$391K ——2.3%
OBIOOrchestra BioMed Holdings, Inc.LTM Mar 2026$238K +11.2%-16.1%0.7%
EPRXEupraxia Pharmaceuticals Inc.LTM Mar 2026$151.18K +13.6%——
BDTXBlack Diamond Therapeutics, Inc.LTM Mar 2026$113K +31.4%——
AARDAardvark Therapeutics, Inc. Common StockLTM Mar 2026$0 ———
Peer median (excluding FENC) $800K+12.4%+0.0%9.9%

Competitors are the stored peer set for FENC. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue01.54M21.25M47.54M44.64M
Cost of Revenue086K1.26M3.18M3.76M
Gross Profit01.45M19.99M44.35M40.88M
Gross Margin—94.4%94.1%93.3%91.6%
Research & Development4.98M3.53M56K307K250K
Selling, General & Admin12.24M20.51M32.71M41.48M46.91M
Operating Expenses17.22M24.19M33.05M41.88M47.22M
Depreciation & Amortization16K149K287K800K103K
EBITDA(17.22M)(22.59M)(12.36M)4.8M(7.45M)
EBITDA Margin—-1471.5%-58.2%10.1%-16.7%
Operating Income(17.22M)(22.74M)(13.06M)2.48M(6.35M)
Operating Margin—-1481.3%-61.4%5.2%-14.2%
Interest Income54K195K441K1.59M787K
Interest Expense126K978K3.39M4.07M2.08M
Other Income / Expenses(123K)(976K)(2.99M)(2.55M)(3.29M)
Income Before Tax(17.35M)(23.71M)(16.05M)(71K)(9.64M)
Pre-Tax Margin—-1544.9%-75.5%-0.1%-21.6%
Income Tax Expense000365K106K
Net Income(17.35M)(23.71M)(16.05M)(436K)(9.74M)
Net Margin—-1544.9%-75.5%-0.9%-21.8%
EPS (Basic)(0.67)(0.95)(0.60)(0.02)(0.36)
EPS (Diluted)(0.67)(0.95)(0.60)(0.02)(0.36)
Weighted Avg Shares26.01M26.28M26.57M27.29M28.58M
Weighted Avg Shares (Diluted)26.01M26.28M26.57M27.29M28.58M

Fennec Pharmaceuticals Inc.

NASDAQ:FENC

Intrinsic Alpha fair value

Locked

Current Price

$13.33

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.